Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Novel starting points for fragment-based drug design against mycobacterial thioredoxin reductase identified using crystallographic fragment screening

Acta Crystallographica Section D Structural Biology(2023)10.1107/s2059798323005223Source: DataRank Database

Novel starting points for fragment-based drug design against mycobacterial thioredoxin reductase identified using crystallographic fragment screening is a research paper published in Acta Crystallographica Section D Structural Biology (2023). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.37)OA: hybridTopics (32)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

J. Wollenhaupt ORCID,M.S. Weiss ORCID,Daniel Kümmel ORCID,Oliver Koch ORCID,Friederike T. Füsser ORCID

Live enrichment

PubMed:37574972 PMC:PMC10478635 OpenAlex:https://openalex.org/W4385799092

Deutsches Zentrum für Infektionsforschung

Grant: TTU 02.906

Deutsche Forschungsgemeinschaft

Grant: KO 4689/5-1

NIAID NIH HHS

Grant: 75N93022C00036

Deutsche Forschungsgemeinschaft

Grant: unidentified

unidentified

FWCI

0.37

Citation Percentile

0.5%

Citation Trend

2024

2025

hybridLicense: cc-by

journalhttps://journals.iucr.org/d/issues/2023/09/00/jb5056/jb5056.pdf

publisherhttps://journals.iucr.org/d/issues/2023/09/00/jb5056/jb5056.pdf

journalhttps://doi.org/10.1107/s2059798323005223

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37574972

repositoryhttps://www.helmholtz-berlin.de/pubbin/oai_publication?VT=1&ID=109584

Fields of Study

Enzyme Structure and FunctionRedox biology and oxidative stressEnzyme function and inhibition

MeSH Terms

Binding SitesHumansMycobacterium tuberculosisThioredoxin-Disulfide ReductaseTuberculosisDrug Design

Keywords

Fragment (logic)Thioredoxin reductaseComputational biologyReductaseChemistryStereochemistryBiologyComputer scienceThioredoxinBiochemistryEnzymeAlgorithmMycobacterium tuberculosisMycobacterium SmegmatisAntituberculotic DrugsCrystallographic Fragment ScreeningThioredoxin-Disulfide ReductaseBinding SitesDrug DesignHumansTuberculosiscrystallographic fragment screening; Mycobacterium tuberculosis; Mycobacterium smegmatis; thioredoxin reductase; antituberculotic drugsResearch Papers

Sustainable Development Goals

SDG 0: Good health and well-being

Novel starting points for fragment-based drug design against mycobacterial thioredoxin reductase identified using crystallographic fragment screening

FAIR Checklist

Authors (5)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)